Novo EVP says new data shows Wegovy stands out in obesity crowd

With sustained weight loss over a two-year period, Novo Nordisk's Wegovy has differentiated itself from existing competitors on the obesity drug market, says Novo Nordisk's EVP Martin Holst Lange. He also thinks the new results could help change the perception of obesity treatment.
Photo: Novo Nordisk / PR
Photo: Novo Nordisk / PR

Novo Nordisk can celebrate obesity drug Wegovy, which is built on the GLP-1 analog semaglutide, as it has demonstrated a significant and sustained weight loss of 15.2 percent in a two-year study.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading